Saturday 17 October 2026 Export SERA’s income statement to Excel — free account

Sera Prognostics, Inc.

Sera Prognostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $81,000.00, up 5.19% from fiscal 2024. In the quarter to June 2026, revenue grew 76.5%, EPS fell 12.5% and free cash flow fell 10.6%, each against the same quarter a year earlier.

2.06 0.03 +1.48%

Follow SERA

Alert me

Market cap: $80.1M
P/E: 0.0×
Fwd P/E: −3.5×
Dividend yield: —
F-score: 4/9
Altman Z: −2.09
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.66

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	9	13	1	1	12	—	—	8	—	—	5	1

Insider Ownership 42.57%

Capital & Financial Ratios $m

Market Cap 80.08

Revenue 0.07

Net Income (33.23)

Free Cash Flow (28.53)

Net Debt (46.44)

Current Ratio 1.98

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (3.50)

P/S ratio 1,485.46

P/B ratio 1.75

Past 5Y EPS Growth —

This Y EPS Growth 1.87%

Next Y EPS Growth 18.63%

Next Y revenue growth 177.78%

Next 5Y EPS Growth 9.06%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 74.41%

10-year low 10-year high

P/B against its own 10 years 61.88%

10-year low 10-year high

EV/Sales against its own 10 years 53.04%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	49	46	39	46
Receivables	11	0	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	61	48	41	48

	2023	2024	2025	Q'26
Payables	1	2	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	24	25	24	24

Compound Annual Growth %

	10y	5y	3y
Sales	—	26.51%	(32.89%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	98.19%	(8.66%)

Revenue $m

	Mar	Sep	Dec	Year
’26	0	—	—	—
’25	0	0	0	0
’24	—	0	0	0
’23	0	0	0	0
’22	0	0	0	0
’21	0	0	0	0
’20	0	0	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(6)	—	—	—
’25	(8)	(5)	(6)	(6)	(26)
’24	5	(6)	(7)	(6)	(14)
’23	(5)	(8)	(8)	(7)	(27)
’22	(10)	(9)	(9)	(7)	(35)
’21	(7)	(6)	(9)	(9)	(32)
’20	(5)	(9)	(4)	(4)	(17)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(6)	—	—	—
’25	(8)	(6)	(7)	(6)	(26)
’24	4	(6)	(7)	(6)	(15)
’23	(5)	(8)	(8)	(7)	(27)
’22	(10)	(9)	(9)	(7)	(35)
’21	(7)	(6)	(10)	(10)	(33)
’20	(5)	(9)	(4)	(4)	(17)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.17)	(0.18)	—	—	—
’25	(0.20)	(0.16)	(0.16)	(0.16)	(0.67)
’24	(0.25)	(0.25)	(0.24)	(0.25)	(0.99)
’23	(0.34)	(0.34)	(0.23)	(0.25)	(1.16)
’22	(0.40)	(0.37)	(0.35)	(0.31)	(1.43)
’21	(3.55)	(3.17)	(0.39)	(0.41)	(2.33)
’20	(0.15)	(3.08)	(3.30)	—	(12.76)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	6.58	1.10	1.15	4.90	1.37	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	15.50	9.48	9.86	12.36	8.73
People
People	Employees	—	—	—	—	71	115	89	57	64	72
	Revenue/emp, $m	—	—	—	0.00	0.00	0.00	0.00	0.01	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	0	0	0	0	0	0	0
	Gross margin, %	—	—	—	(2,577.78)	56.00	54.88	27.99	31.37	(6.49)	(102.47)
	EBT	—	—	—	(17)	(20)	(35)	(44)	(36)	(33)	(32)
	EBT margin, %	—	—	—	(45,891.67)	(79,392.00)	(42,693.90)	(16,487.31)	(11,843.79)	(42,724.68)	(39,417.28)
	Net income	—	0	—	(17)	(20)	(35)	(44)	(36)	(33)	(32)
	Depreciation	—	—	—	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.02	0.01	0.01	0.01	0.00	0.00
	Earnings	—	—	—	(0.54)	(12.76)	(2.33)	(1.43)	(1.16)	(0.99)	(0.67)
	Cash flow	—	—	—	(0.63)	(10.84)	(2.11)	(1.12)	(0.87)	(0.43)	(0.54)
	Capex	—	—	—	0.00	(0.10)	(0.09)	(0.02)	0.01	(0.03)	(0.02)
	Free cash flow	—	—	—	(0.63)	(10.94)	(2.20)	(1.14)	(0.87)	(0.46)	(0.55)
	Book value	—	—	—	(3.47)	1.59	9.24	3.20	2.25	1.44	1.58
	Shares, m	—	—	—	31	2	15	31	31	33	48
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	537.93	537.93	1,256.97	151.25	608.72	2,287.26	1,735.84
	P/B	—	—	—	0.00	0.00	0.74	0.41	2.66	5.65	1.86
	EV/Sales	—	—	—	(1,524.79)	(1,524.79)	(24.26)	(155.01)	448.97	1,895.45	1,251.90
	EV/FCF	—	—	—	3.11	3.11	0.06	1.17	(5.09)	(14.63)	(3.70)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(19)	(17)	(32)	(35)	(27)	(14)	(26)
	Capex	—	—	—	0	0	(1)	(1)	0	(1)	(1)
	Free cash flow	—	—	—	(19)	(17)	(33)	(35)	(27)	(15)	(26)
Balance, $m
Balance, $m	Working capital	—	—	—	16	2	102	75	37	23	17
	Total debt	—	—	—	127	4	0	1	0	0	—
	Net debt	—	—	—	105	(9)	(105)	(82)	(49)	(46)	(39)
	Shareholders’ equity	—	—	—	(107)	2	139	99	70	48	75
Returns, %
Returns, %	ROA	—	—	—	(142.06)	(104.31)	(43.27)	(33.56)	(34.23)	(39.16)	(36.59)
	ROIC	—	—	—	0.00	0.00	(66.03)	(169.18)	(116.98)	(1,459.33)	(63.01)
	ROE	—	—	—	14.23	17.10	(538.85)	(37.21)	(42.86)	(55.78)	(51.83)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
APYX Apyx Medical Corporation	$107.8M	— (loss-making)	— (loss-making)	+22.08% (above 0%: growing)	n/m	−137.38% (below 0%: shrinking)	63.89%	(13.01%)	Compare
LUCD Lucid Diagnostics Inc.	$105.7M	— (loss-making)	— (loss-making)	+26.74% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	1.97%	(868.45%)	Compare
ZOMDF Zomedica Corp.	$95.4M	— (loss-making)	— (loss-making)	+36.59% (above 0%: growing)	n/m	+40.48% (above 0%: growing)	63.51%	(42.92%)	Compare
HYPR Hyperfine, Inc.	$82.7M	— (loss-making)	— (loss-making)	+44.81% (above 0%: growing)	n/m	+13.43% (above 0%: growing)	50.72%	(216.93%)	Compare
SERA Sera Prognostics, Inc.	$80.1M	— (loss-making)	— (loss-making)	+76.47% (above 0%: growing)	n/m	−10.58% (below 0%: shrinking)	(66.67%)	(33,346.67%)
LUNG Pulmonx Corporation	$79.5M	— (loss-making)	— (loss-making)	−4.62% (below 0%: shrinking)	n/m	−31.79% (below 0%: shrinking)	77.97%	(39.80%)	Compare
OM Outset Medical, Inc.	$76.6M	— (loss-making)	— (loss-making)	+0.69% (above 0%: growing)	n/m	−90.54% (below 0%: shrinking)	41.99%	(49.55%)	Compare
ECOR electroCore, Inc.	$75.3M	— (loss-making)	— (loss-making)	+28.03% (above 0%: growing)	n/m	−443.52% (below 0%: shrinking)	86.53%	(29.33%)	Compare
LNSR LENSAR, Inc.	$74.1M	2.0×	7.1×	+18.37% (above 0%: growing)	n/m	+96.81% (above 0%: growing)	59.27%	12.94%	Compare
Median of peers	$81.1M	—	—	+24.41%	—	−19.42%	61.39%	(41.36%)

All 149 Medical Devices stocks →

Sera Prognostics, Inc. (SERA) key facts

Concern: Sera Prognostics, Inc. reported a net loss of $31.9 million, or a loss of $0.67 per share, for fiscal 2025.
Strength: Sera Prognostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $81,000.00, up 5.19% from fiscal 2024.
Sera Prognostics, Inc. (SERA) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SERA traded at $2.06, a market capitalization of $80.1 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1,485× sales.
Return on equity was −51.8% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −2.09 (distress zone) for fiscal 2025.